Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

by Zacks Equity Research

IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.

Allogene's Q3 Loss Narrower Than Expected, Sales Nil

by Zacks Equity Research

ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.

IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line

by Zacks Equity Research

Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging

by Zacks Equity Research

DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.

Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus

by Zacks Equity Research

IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.

Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View

by Zacks Equity Research

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.

Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View

by Zacks Equity Research

JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents.

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up

by Zacks Equity Research

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.

Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth

by Zacks Equity Research

PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.

Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth

by Zacks Equity Research

ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.

SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program

by Zacks Equity Research

Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.

Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated

by Zacks Equity Research

PRGO reports weaker-than-expected third-quarter 2024 results. Though management updates top-line guidance for 2024, it reaffirms the bottom-line outlook.

BIIB vs. MYGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

BIIB vs. MYGN: Which Stock Is the Better Value Option?

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

by Zacks Equity Research

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

Are Investors Undervaluing Biogen (BIIB) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Biogen (BIIB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View

by Zacks Equity Research

BIIB's Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.

Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks

by Zacks Equity Research

Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

by Zacks Equity Research

Sage Therapeutics' third-quarter 2024 earnings miss estimates. Stock falls in after-hours trading.

Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Biogen (BIIB) delivered earnings and revenue surprises of 8.22% and 0.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?

by Zacks Equity Research

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.

ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

On CDXC's third-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its marketed product Niagen and updates on the pipeline.

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

Zoetis Gears Up to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

ZTS' higher companion animal product sales are likely to have driven revenues in third-quarter 2024 in both the United States and International segments.